Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR

Alessandra Felici, Emilio Bria, Giampaolo Tortora, Francesco Cognetti, Michele Milella

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

With seven targeted agents, directed against the VEGF/VEGF receptor (VEGFR) axis or the mTOR pathway, approved for the treatment of metastatic renal cell carcinoma and more active agents in advanced phase of clinical testing, questions have arisen with regard to their optimal use, either in combination or in sequence. One of the most compelling (and debated) issues is whether continued VEGF/VEGFR inhibition with agents hitting the same targets (TKI-TKI) affords better results than switching mechanisms of action by alternating VEGFR and mTOR inhibition (TKI-mTOR). In this article, the authors review the (little) available evidence coming from randomized Phase III clinical trials and try to fill in the (many) remaining gaps using evidence from small-size, single-arm Phase II studies and retrospective series, as well as reviewing preclinical evidence supporting either strategy.

Original languageEnglish
Pages (from-to)1545-1557
Number of pages13
JournalExpert Review of Anticancer Therapy
Volume12
Issue number12
DOIs
Publication statusPublished - Dec 2012

Fingerprint

Vascular Endothelial Growth Factor Receptor
Renal Cell Carcinoma
Vascular Endothelial Growth Factor A
Phase III Clinical Trials
Therapeutics
Randomized Controlled Trials
Retrospective Studies

Keywords

  • metastatic
  • mTOR inhibitors
  • renal cell carcinoma
  • second-line treatment
  • sequential therapy
  • VEGF receptor-tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Sequential therapy in metastatic clear cell renal carcinoma : TKI-TKI vs TKI-mTOR. / Felici, Alessandra; Bria, Emilio; Tortora, Giampaolo; Cognetti, Francesco; Milella, Michele.

In: Expert Review of Anticancer Therapy, Vol. 12, No. 12, 12.2012, p. 1545-1557.

Research output: Contribution to journalArticle

@article{82c95abd567d484f8fbde51fc2084cc1,
title = "Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR",
abstract = "With seven targeted agents, directed against the VEGF/VEGF receptor (VEGFR) axis or the mTOR pathway, approved for the treatment of metastatic renal cell carcinoma and more active agents in advanced phase of clinical testing, questions have arisen with regard to their optimal use, either in combination or in sequence. One of the most compelling (and debated) issues is whether continued VEGF/VEGFR inhibition with agents hitting the same targets (TKI-TKI) affords better results than switching mechanisms of action by alternating VEGFR and mTOR inhibition (TKI-mTOR). In this article, the authors review the (little) available evidence coming from randomized Phase III clinical trials and try to fill in the (many) remaining gaps using evidence from small-size, single-arm Phase II studies and retrospective series, as well as reviewing preclinical evidence supporting either strategy.",
keywords = "metastatic, mTOR inhibitors, renal cell carcinoma, second-line treatment, sequential therapy, VEGF receptor-tyrosine kinase inhibitor",
author = "Alessandra Felici and Emilio Bria and Giampaolo Tortora and Francesco Cognetti and Michele Milella",
year = "2012",
month = "12",
doi = "10.1586/era.12.149",
language = "English",
volume = "12",
pages = "1545--1557",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "12",

}

TY - JOUR

T1 - Sequential therapy in metastatic clear cell renal carcinoma

T2 - TKI-TKI vs TKI-mTOR

AU - Felici, Alessandra

AU - Bria, Emilio

AU - Tortora, Giampaolo

AU - Cognetti, Francesco

AU - Milella, Michele

PY - 2012/12

Y1 - 2012/12

N2 - With seven targeted agents, directed against the VEGF/VEGF receptor (VEGFR) axis or the mTOR pathway, approved for the treatment of metastatic renal cell carcinoma and more active agents in advanced phase of clinical testing, questions have arisen with regard to their optimal use, either in combination or in sequence. One of the most compelling (and debated) issues is whether continued VEGF/VEGFR inhibition with agents hitting the same targets (TKI-TKI) affords better results than switching mechanisms of action by alternating VEGFR and mTOR inhibition (TKI-mTOR). In this article, the authors review the (little) available evidence coming from randomized Phase III clinical trials and try to fill in the (many) remaining gaps using evidence from small-size, single-arm Phase II studies and retrospective series, as well as reviewing preclinical evidence supporting either strategy.

AB - With seven targeted agents, directed against the VEGF/VEGF receptor (VEGFR) axis or the mTOR pathway, approved for the treatment of metastatic renal cell carcinoma and more active agents in advanced phase of clinical testing, questions have arisen with regard to their optimal use, either in combination or in sequence. One of the most compelling (and debated) issues is whether continued VEGF/VEGFR inhibition with agents hitting the same targets (TKI-TKI) affords better results than switching mechanisms of action by alternating VEGFR and mTOR inhibition (TKI-mTOR). In this article, the authors review the (little) available evidence coming from randomized Phase III clinical trials and try to fill in the (many) remaining gaps using evidence from small-size, single-arm Phase II studies and retrospective series, as well as reviewing preclinical evidence supporting either strategy.

KW - metastatic

KW - mTOR inhibitors

KW - renal cell carcinoma

KW - second-line treatment

KW - sequential therapy

KW - VEGF receptor-tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84871479033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871479033&partnerID=8YFLogxK

U2 - 10.1586/era.12.149

DO - 10.1586/era.12.149

M3 - Article

C2 - 23253221

AN - SCOPUS:84871479033

VL - 12

SP - 1545

EP - 1557

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 12

ER -